COVID-19: Oxford/AstraZenica vaccine has 'similar effect' against Kent variant, researchers find

·1-min read

The Oxford/AstraZenica vaccine remains effective against the coronavirus variant first detected in Kent and the South East of the UK, researchers have found.

The Oxford University researchers who developed the jab say it has a similar efficacy against the variant compared to the original COVID-19 strain it was tested against.

Andrew Pollard, Professor of Paediatric Infection and Immunity, and chief investigator on the Oxford vaccine trial, said:
"Data from our trials of the ChAdOx1 vaccine in the United Kingdom indicate that the vaccine not only protects against the original pandemic virus, but also protects against the novel variant, B.1.1.7, which caused the surge in disease from the end of 2020 across the UK."